In This Article:
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA.
Details of the presentation are as follows:
Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic Window
Session: Understanding Toxicity Challenges & Improving Safety Profiles to Widen the Therapeutic Window
Speaker: Richard Kenney, M.D., Chief Medical Officer of Sonnet
Date and Time: Thursday, May 15, 2025 at 11:15 AM ET
As part of the session, Dr. Kenney will discuss:
-
Exploring the strategy behind the introduction of receptor bias to reduce toxicity and improve efficacy;
-
Key strategies for optimizing cytokine potency and mitigating their inherent toxicity while considering the role of the therapeutic index in determining the clinical efficacy and safety of cytokine-based therapies; and
-
Examining whether toxicity is the primary limiting factor in achieving therapeutic benefit and considering alternative factors that may influence the ‘therapeutic window’.
For more information, please visit the Summit website here.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC) (NCT05756907). The Company is also evaluating its second program using this platform, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer.